投稿ビュー
Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases - Seeking Alpha
Seeking Alpha | Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases Seeking Alpha Sangamo just became the first company to do in vivo genome editing in the clinic. One of the four trials Sangamo has in the clinical is SB-525. Pfizer agreed to potential milestone payments of $475 million plus royalties to collaborate with them on ... |
評価
おすすめ
タグ
転職
"
"@type":
"@type":"NewsArticle"
"Auga Group"
"C" grade Nevada infrastructure
"Errol Oh"
"Jane Goodyear"
"Optimistically Cautious"
"a man and his prostate"
"akcijų pardavimas"
"analytics:simplereach:id":"54
"author":"Art Berman"
"author":"Brad McMillan"
"author":"Bryan Rich"
"author":"Christopher Helman"
"author":"Claire Poole"
"author":"Clare O'Connor"
"author":"David Blackmon"